Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Consensus Rating of “Moderate Buy” by Analysts

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) has been given a consensus rating of “Moderate Buy” by the seven analysts that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $13.60.

OBIO has been the subject of several research analyst reports. Wall Street Zen cut Orchestra BioMed from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Orchestra BioMed in a research note on Thursday, May 14th. Weiss Ratings downgraded Orchestra BioMed from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, April 21st. B. Riley Financial dropped their price target on Orchestra BioMed from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Finally, Barclays lifted their price target on shares of Orchestra BioMed from $12.00 to $13.00 and gave the company an “overweight” rating in a report on Wednesday, May 13th.

Orchestra BioMed Stock Performance

Orchestra BioMed stock opened at $4.19 on Friday. The company has a current ratio of 7.03, a quick ratio of 7.01 and a debt-to-equity ratio of 0.35. The firm has a 50-day moving average of $4.03 and a 200-day moving average of $4.18. The firm has a market cap of $250.90 million, a P/E ratio of -4.32 and a beta of 0.49. Orchestra BioMed has a 1-year low of $2.20 and a 1-year high of $5.42.

Orchestra BioMed (NASDAQ:OBIO) last posted its earnings results on Tuesday, May 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.07. The company had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.92 million. Orchestra BioMed had a negative return on equity of 157.46% and a negative net margin of 166.96%. Sell-side analysts expect that Orchestra BioMed will post -1.47 EPS for the current year.

Insiders Place Their Bets

In related news, Director Eric S. Fain bought 20,000 shares of the business’s stock in a transaction dated Thursday, May 14th. The shares were purchased at an average price of $4.13 per share, with a total value of $82,600.00. Following the purchase, the director owned 91,709 shares of the company’s stock, valued at approximately $378,758.17. This trade represents a 27.89% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Darren Sherman sold 15,000 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $3.87, for a total transaction of $58,050.00. Following the transaction, the insider owned 1,184,327 shares in the company, valued at $4,583,345.49. This represents a 1.25% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders purchased 39,636 shares of company stock worth $158,081. 7.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Orchestra BioMed

Several large investors have recently bought and sold shares of the company. Bank of America Corp DE grew its holdings in shares of Orchestra BioMed by 42.0% during the 4th quarter. Bank of America Corp DE now owns 23,780 shares of the company’s stock worth $95,000 after acquiring an additional 7,036 shares during the period. Creative Planning bought a new position in shares of Orchestra BioMed in the 2nd quarter worth approximately $40,000. XTX Topco Ltd purchased a new position in shares of Orchestra BioMed in the 2nd quarter valued at approximately $45,000. Marshall Wace LLP purchased a new position in shares of Orchestra BioMed in the 2nd quarter valued at approximately $133,000. Finally, NewEdge Advisors LLC bought a new stake in shares of Orchestra BioMed during the second quarter valued at approximately $118,000. 53.20% of the stock is owned by institutional investors.

About Orchestra BioMed

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.